GB2541348A - Clopidogrel for use in the treatment of benign prostatic hyperplasia - Google Patents

Clopidogrel for use in the treatment of benign prostatic hyperplasia Download PDF

Info

Publication number
GB2541348A
GB2541348A GB1621183.1A GB201621183A GB2541348A GB 2541348 A GB2541348 A GB 2541348A GB 201621183 A GB201621183 A GB 201621183A GB 2541348 A GB2541348 A GB 2541348A
Authority
GB
United Kingdom
Prior art keywords
clopidogrel
treatment
benign prostatic
prostatic hyperplasia
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB1621183.1A
Other versions
GB201621183D0 (en
Inventor
Szendrei Levente
Berecz Roland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skillpharm Kft
Original Assignee
Skillpharm Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skillpharm Kft filed Critical Skillpharm Kft
Publication of GB201621183D0 publication Critical patent/GB201621183D0/en
Publication of GB2541348A publication Critical patent/GB2541348A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

The present invention relates to the novel use of clopidogrel and pharmaceutically acceptable salts thereof. More precisely, the invention relates to the use of clopidogrel and pharmaceutically acceptable salts thereof against benign prostatic hyperplasia. Specifically, the invention relates to clopidogrel and its pharmaceutically acceptable salts for use in the treatment of benign prostatic hyperplasia (BPH), and to the use of clopidogrel and its pharmaceutically acceptable salts for the preparation of a pharmaceutical composition useful for the treatment of benign prostatic hyperplasia. Further, the invention also relates to a pharmaceutical composition for the use in the treatment of BPH, comprising clopidogrel or its pharmaceutically acceptable salts as active ingredient.
GB1621183.1A 2014-06-13 2015-06-11 Clopidogrel for use in the treatment of benign prostatic hyperplasia Pending GB2541348A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1400294A HUP1400294A2 (en) 2014-06-13 2014-06-13 Novel application of clopidogrel
PCT/HU2015/000053 WO2015189650A1 (en) 2014-06-13 2015-06-11 Clopidogrel for use in the treatment of benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
GB201621183D0 GB201621183D0 (en) 2017-01-25
GB2541348A true GB2541348A (en) 2017-02-15

Family

ID=89991514

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1621183.1A Pending GB2541348A (en) 2014-06-13 2015-06-11 Clopidogrel for use in the treatment of benign prostatic hyperplasia

Country Status (3)

Country Link
GB (1) GB2541348A (en)
HU (1) HUP1400294A2 (en)
WO (1) WO2015189650A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030324A2 (en) * 1999-10-27 2001-05-03 Aufsess Joachim G Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (en) 1982-07-13 1986-05-16 Sanofi Sa NOVEL THIENO (3, 2-C) PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATION
FR2623810B2 (en) 1987-02-17 1992-01-24 Sanofi Sa ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP0748627A3 (en) 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for use in the treatment of benign prostatic hyperplasia
FR2744918B1 (en) 1996-02-19 1998-05-07 Sanofi Sa NEW COMBINATIONS OF ACTIVE INGREDIENTS CONTAINING THIENO (3,2-C) PYRIDINE DERIVATIVE AND AN ANTITHROMBOTIC
AU3303399A (en) 1998-02-20 1999-09-06 Vanson, Inc. Composition and method for reducing transpiration in plants
ZA991319B (en) 1998-02-20 2000-11-20 Ortho Mcneil Pharm Inc Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
FR2779726B1 (en) 1998-06-15 2001-05-18 Sanofi Sa POLYMORPHIC FORM OF CLOPIDOGREL HYDROGENOSULFATE
CN1343128B (en) 1999-03-17 2010-04-21 第一制药株式会社 Medicinal compositions
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
HUP0200438A3 (en) 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
EA013399B1 (en) 2002-02-07 2010-04-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Treating benign prostate hyperplasia with a selective androgen receptor modulator (sarm)
GB2393181A (en) 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel
DE10305984A1 (en) 2003-02-13 2004-09-02 Helm Ag Salts of organic acids with clopidogrel and their use in the manufacture of pharmaceutical formulations
WO2005070464A2 (en) 2004-01-21 2005-08-04 Biofarma Ilac Sanayi Ve Ticaret A.S. A tablet formulation of clopidogrel bisulphate
ZA200608569B (en) 2004-04-20 2007-12-27 Sanofi Aventis Polymorphic forms of methyl (+)-(S)-alpha- (2-chlorophenyl)-6, 7-dinydrothieno[3,2-C] pyridine-5(4H) acetate hydrobromide, clopidrogel hydrobromide
KR20070009851A (en) 2005-07-14 2007-01-19 씨제이 주식회사 Pharmaceutical compositions containing clopidogrel bisulfate
KR20070044323A (en) 2005-10-24 2007-04-27 에스케이케미칼주식회사 Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate
IS2385B (en) 2006-02-10 2008-07-15 Actavis Group Hf. Clopidogrel bisulfate pharmaceutical compositions
PT1847258E (en) 2006-04-13 2010-06-22 Riemser Specialty Production G Partial glycerides as lubricants in pharmaceutical compositions comprising thieno[3,2-c]pyridine derivatives
AT506095A1 (en) 2007-12-03 2009-06-15 Volopharm Gmbh USE OF PROTEASES
ES2376057T3 (en) 2008-02-26 2012-03-08 Laboratorios Lesvi, S.L. PHARMACEUTICAL FORMULATIONS CONTAINING CLOPIDOGREL.
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
WO2014014177A1 (en) 2012-07-18 2014-01-23 조선대학교 산학협력단 Composition comprising dendropanax morbifera extract or compound derived therefrom as active ingredient for preventing and treating benign prostatic hyperplasia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030324A2 (en) * 1999-10-27 2001-05-03 Aufsess Joachim G Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AURÉLIEN DESCAZEAUD, A L, AURÉLIEN DESCAZEAUD, GREGOIRE ROBERT, ABDEL RAHMENE AZZOUSI, CHARLES BALLEREAU, BERTRAND LUKACS, OLIVIER: "Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy: a review", BJU INTERNATIONAL, BLACKWELL SCIENCE, vol. 103, no. 9, 1 May 2009 (2009-05-01), pages 1162 - 1165, XP055209303, ISSN: 14644096, DOI: 10.1111/j.1464-410X.2008.08284.x *
KEVIN S. CHOE, DAVID CORREA, BS, ASHESH B JANI, STANLEY L LIAUW: "The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy", CANCER, ¬JOHN WILEY & SONS| :, vol. 116, no. 7, 1 April 2010 (2010-04-01), pages 1820 - 1826, XP055209223, ISSN: 0008543X, DOI: 10.1002/cncr.24890 *

Also Published As

Publication number Publication date
WO2015189650A1 (en) 2015-12-17
HUP1400294A2 (en) 2015-12-28
GB201621183D0 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MD20170016A2 (en) Aminopyrimidinyl compounds as JAK inhibitors
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MD4650B1 (en) Quinazoline derivatives used to treat HIV
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2015011898A (en) Pyrazolo compounds and uses thereof.
MA39986A (en) Purine derivatives as cd73 inhibitors for the treatment of cancer
MY187047A (en) Selective pyy compounds and uses thereof
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2017008518A (en) Isoquinoline compounds for the treatment of hiv.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
CL2015002897A1 (en) Bace1 inhibitors
TW201613864A (en) Novel compounds
MD20170011A2 (en) Imidazopyridazine compounds
MX2021008432A (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders.
EA201791009A1 (en) COMPOSITIONS CONTAINING CYCLOSPORIN
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
GB2541348A (en) Clopidogrel for use in the treatment of benign prostatic hyperplasia
MX2018003564A (en) Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer.